Idhifa, enasidenib
Named-patient access overview. Idhifa is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
This page is informational, not medical advice.
Ask about Idhifa
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Idhifa
Idhifa (enasidenib) is an oral, once-daily targeted therapy manufactured by Bristol-Myers Squibb following its acquisition of Celgene. It is a small-molecule inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) and is indicated for adults with relapsed or refractory acute myeloid leukemia who carry a confirmed IDH2 mutation. Idhifa works by inhibiting the mutant IDH2 enzyme, reducing levels of the oncometabolite 2-hydroxyglutarate, and allowing leukemic cells to resume more normal differentiation.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Idhifa is supplied as 50 mg and 100 mg tablets. It is taken once daily by mouth, with or without food, and is generally continued until disease progression or unacceptable toxicity. Because Idhifa is an oral oncology agent at room-temperature storage, the cold-chain layer that complicates many specialty medicines is not required. It does, however, require careful supply continuity, since interruption of therapy can let leukemic burden rebuild.
For international patients whose home-country formulary does not include Idhifa, or where the IDH2 mutation-positive subset is too small to support local stocking, a named-patient pathway from the United States is often the most practical route.
Who Idhifa is for
Idhifa is generally considered for adults with acute myeloid leukemia that has relapsed after, or is refractory to, prior therapy, and whose tumor carries a documented IDH2 mutation on a validated molecular assay. The treating hematologist confirms the mutation status, weighs prior therapy, performance status, and other factors, and decides whether to initiate Idhifa. Differentiation syndrome is a serious potential adverse event, and the prescribing physician should be prepared to monitor and manage it.
How Reserve Meds coordinates Idhifa
- Patient or treating hematologist submits a named-patient request through Reserve Meds intake.
- Our clinical team verifies appropriateness of Idhifa for the patient, including IDH2 mutation confirmation and destination country.
- The treating physician issues a prescription and a brief clinical justification.
- Country-specific named-patient program or personal-import documentation is prepared.
- Idhifa is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician, hospital pharmacy, or approved address, with quantity sized to the prescribed dosing interval.
Pricing and what shapes it
Idhifa's total cost for international patients depends on the medicine, destination-country import duties and value-added tax, logistics fees, and the Reserve Meds coordination fee. Because Idhifa is dispensed in defined tablet quantities rather than a single dose, the cost scales with the prescribed daily dose and the cycle length. Once intake is complete and destination confirmed, our coordinator issues a firm written quote covering the full landed cost before any wire is requested.
Timing expectations
We give you a written timeline estimate for your case before you commit. The dominant variables are destination-country regulatory processing, completeness of the physician package, and customs clearance. Because Idhifa is an oral tablet at ambient temperature, transit risk is lower than for refrigerated biologics. Reserve Meds assigns each case a single point of contact who maintains continuity from intake through delivery and refill.
Clinical trials and expanded access
On 17 October 2026 we searched ClinicalTrials.gov, the clinical study registry of the US National Library of Medicine, for studies that list enasidenib as an intervention. The search found studies that are recruiting or not yet recruiting. See the current list on ClinicalTrials.gov.
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Idhifa in every market we coordinate. Each page below covers the destination-country regulatory pathway, how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling. Tap any country to read the full deep-dive.
Storage and handling, in plain language
Idhifa tablets are stable at room temperature in the original blister and bottle packaging. They should be kept dry, away from direct sunlight, and out of reach of children. There is no cold-chain requirement, which simplifies international transit. Reserve Meds packages each shipment with tamper-evident seals and documentation that matches the wholesaler's serial records, so the receiving physician can verify provenance on arrival.
Documentation the physician will be asked to provide
The typical package includes a current prescription, a brief clinical justification letter, a copy of the physician's license, the laboratory report confirming the IDH2 mutation, and the destination-country named-patient or personal-import form where applicable. Reserve Meds prepares the country-specific paperwork; the physician supplies the clinical pieces. We aim to keep the physician's workload to under thirty minutes per case.
Privacy and data handling
Patient information collected through Reserve Meds intake is handled under HIPAA standards in the United States and the privacy regimes that apply in the destination country, including UAE PDPL, KSA PDPL, India DPDPA, and the EU GDPR where relevant. We share only the minimum necessary information with the prescribing physician, the wholesaler, the carrier, and any regulator who requires submission.
Start a request for Idhifa
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Ask about a medicine Or message us on WhatsApp
Reserved for you.
Frequently asked questions
How can I get Idhifa if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Idhifa for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Idhifa through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Idhifa. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Idhifa through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Idhifa to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Idhifa to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Idhifa cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Idhifa?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.